Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2227084 | 1.00 | NR1H2 (0.42) | NR1H2MEN1KMT2APREPCTSK | |
| SCHEMBL24821656 | 1.00 | NR1H2 (0.42) | NR1H2MEN1KMT2APREPCTSK | |
| SCHEMBL4040236 | 0.88 | NR1H2 (0.37) | NR1H2MEN1KMT2APREPCTSK | |
| SCHEMBL4040230 | 0.88 | NR1H2 (0.37) | NR1H2MEN1KMT2APREPCTSK | |
| SCHEMBL4049137 | 0.86 | PREP (0.35) | NR1H2PREPCTSKLMNANPSR1 | |
| SCHEMBL4049132 | 0.86 | PREP (0.35) | NR1H2PREPCTSKLMNANPSR1 | |
| SCHEMBL22950853 | 0.83 | PREP (0.35) | NR1H2MEN1KMT2APREPCTSK | |
| SCHEMBL4042751 | 0.82 | LMNA (0.36) | NR1H2MEN1KMT2APREPCTSK | |
| SCHEMBL13944483 | 0.82 | CTSK (0.42) | NR1H2MEN1KMT2APREPCTSK | |
| SCHEMBL4197155 | 0.82 | CTSK (0.42) | NR1H2MEN1KMT2APREPCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327434-A1 | FUSED TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| EP-4361157-A1 | FUSED TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2024-05-01 | — | — | EP | disclosed |
| CN-117255793-A | Fused tetracyclic compound, preparation method thereof and application thereof in medicines | 江苏恒瑞医药股份有限公司 | 2023-12-19 | — | — | CN | disclosed |
| US-8273767-B2 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2012-09-25 | — | — | US | disclosed |
| US-7947711-B2 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2011-05-24 | — | — | US | disclosed |
| US-20110098285-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2011-04-28 | — | — | US | disclosed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20090054420-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090005575-A1 | Preparation of diazapentalene derivatives via epoxydation of dihydropyrroles | AMURA THERAPEUTICS LTD. (GB) | 2009-01-01 | — | — | US | disclosed |
| WO-2007017698-A1 | PREPARATION OF DIAZAPENTALENE DERIVATIVES VIA EPOXYDATION OF DIHYDROPYRROLES | AMURA THERAPEUTICS LIMITED (GB) | 2007-02-15 | — | — | WO | disclosed |
| US-7153889-B2 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060194798-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2006-08-31 | — | — | US | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| EP-1569637-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | Abbott Laboratories (US) | 2005-09-07 | — | — | EP | disclosed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | disclosed |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004043458-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2004-05-27 | — | — | WO | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098285-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | NR1H2 442/4885MEN1 1149/4885KMT2A 1561/4885 |
| US-20060194798-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH2 | NR1H2 442/4885MEN1 1149/4885KMT2A 1561/4885 |
| US-20240327434-A1 | FUSED TETRACYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF IN MEDICINE | KRAS, NRAS, HRAS | NR1H2 531/4885MEN1 159/4885KMT2A 4091/4885 |
| US-20090005575-A1 | Preparation of diazapentalene derivatives via epoxydation of dihydropyrroles | PTGDR2, PTGER2, PTGDR | NR1H2 384/4885MEN1 1777/4885KMT2A 4154/4885 |
| US-20090054420-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | NR1H2 442/4885MEN1 1149/4885KMT2A 1561/4885 |
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | NR1H2 106/4885MEN1 3247/4885KMT2A 3867/4885 |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | HRH3, HRH4, HRH1 | NR1H2 495/4885MEN1 711/4885KMT2A 1877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.